Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-Benzyladriamycin-14-valerate (AD 198)

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 223-230

  Cai, Chun ^a   Lothstein, Leonard ^a   Morrison, R Ray ^b   Hofmann, Polly A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; BETA TUBULIN; CALCIUM; DESMIN; DOXORUBICIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MYOSIN HEAVY CHAIN; N BENZYLDOXORUBICIN 14 VALERATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOLAMBAN; PROTEIN KINASE C EPSILON; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; TROPONIN I; AMP-ACTIVATED PROTEIN KINASE KINASE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; N-BENZYLADRIAMYCIN-14-VALERATE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART PROTECTION; HEART WEIGHT; IN VIVO STUDY; ISOLATED HEART; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARDIOMYOPATHIES; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; TOXICITY; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CALCIUM; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INDICATORS AND REAGENTS; MALE; MASS SPECTROMETRY; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; POLY ADENOSINE DIPHOSPHATE RIBOSE; PROTEIN KINASE C-EPSILON; PROTEIN KINASES; RATS; RATS, WISTAR;

EID: 77957223613     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167965     Document Type: Article

References (34)

1. Andreadou I, Sigala F, Iliodromitis EK, Papaefthimiou M, Sigalas C, Aligiannis N, Savvari P, Gorgoulis V, Papalabros E, and Kremastinos DT (2007) Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 42: 549-558.
2. Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, and Lothstein L (2002) Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther 1:469-481.
3. Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, and Arsura M (2004) Circumvention of nuclear factor κB-induced chemoresistance by cytoplasmic-targeted anthracyclines. Mol Pharmacol 65: 1038-1047. (Pubitemid 38420510)
4. Böhm M, Thoenes M, Neuberger HR, Gräber S, Reil JC, Bramlage P, and Volpe M (2009) Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 30:1364-1371.
5. Bolli R, Li QH, Tang XL, Guo Y, Xuan YT, Rokosh G, and Dawn B (2007) The late phase of preconditioning and its natural clinical application-gene therapy. Heart Fail Rev 12:189-199. (Pubitemid 350176692)
6. Budas GR, Churchill EN, and Mochly-Rosen D (2007) Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res 55:523-536.
7. Casini S, Tan HL, Demirayak I, Remme CA, Amin AS, Scicluna BP, Chatyan H, Ruijter JM, Bezzina CR, van Ginneken AC, et al. (2010) Tubulin polymerization modifies cardiac sodium channel expression and gating. Cardiovasc Res 85:691-700.
8. de Beer EL, Bottone AE, van Rijk MC, van der Velden J, and Voest EE (2002) Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. Br J Pharmacol 135:1707-1714.
9. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, and Kapelko VI (2003) Alterations in myocardial cytoskeletal and regulatory protein expression following a single doxorubicin injection. J Cardiovasc Pharmacol 41: 788-794. (Pubitemid 36523183)
10. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610.
11. Frishman WH, Sung HM, Yee HC, Liu LL, Einzig AI, Dutcher J, and Keefe D (1996) Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 21:225-286.
12. Gobeil S, Boucher CC, Nadeau D, and Poirier GG (2001) Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 8:588-594.
13. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, and Rosenberg SA (1981) Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94:430-435.
14. Hofmann PA, Israel M, Koseki Y, Laskin J, Gray J, Janik A, Sweatman TW, and Lothstein L (2007) N-benzyladriamycin-14-valerate (AD 198): a noncardiotoxic anthracycline that is cardioprotective through PKC-? activation. J Pharmacol Exp Ther 323:658-664.
15. Horwich TB, Kalantar-Zadeh K, MacLellan RW, and Fonarow GC (2008) Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155:883-889.
16. Iliskovic N, Li T, Khaper N, Palace V, and Singal PK (1998) Modulation of adriamycin- induced changes in serum free fatty acids, albumin and cardiac oxidative stress. Mol Cell Biochem 188:161-166.
17. 2+ spark rate. Circ Res 104:787-795.
18. Leary PJ, Rajasekaran S, Morrison RR, Tuomanen EI, Chin TK, and Hofmann PA (2008) A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation. Am J Physiol Heart Circ Physiol 294:H2775-H2784.
19. Liu B, Li H, Qu H, and Sun B (2006) Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. J Biochem Mol Biol 39:759-765.
20. Lothstein L, Rodrigues PJ, Sweatman TW, and Israel M (1998) Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anti-Cancer Drugs 9:58-66. (Pubitemid 28088180)
21. Maejima Y, Adachi S, Ito H, Hirao K, and Isobe M (2008) Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7:125-136. (Pubitemid 351359646)
22. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
23. Priebe HJ (2000) The aged cardiovascular risk patient. Br J Anaesth 85:763-778.
24. Roaten JB, Kazanietz MG, Caloca MJ, Bertics PJ, Lothstein L, Parrill AL, Israel M, and Sweatman TW (2002) Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity. Mol Cancer Ther 1:483-492.
25. Roaten JB, Kazanietz MG, Sweatman TW, Lothstein L, Israel M, and Parrill AL (2001) Molecular models of by N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-δ. J Med Chem 44:1028-1034.
26. Schultz PN, Beck ML, Stava C, and Vassilopoulou-Sellin R (2003) Health profiles in 5836 long-term cancer survivors. Int J Cancer 104:488-495.
27. Smyth JW, Hong TT, Gao D, Vogan JM, Jensen BC, Fong TS, Simpson PC, Stainier DY, Chi NC, and Shaw RM (2010) Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium. J Clin Invest 120:266-279.
28. Swain SM, Whaley FS, and Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879.
29. Sweatman TW and Israel M (1996) Anthracyclines, in Cancer Therapeutics: Experimental and Clinical Agents (Teicher BA ed) pp 113-136, Humana Press Inc, Totowa, NJ.
30. Sweatman TW, Seshadri R, and Israel M (1999) Pharmacology of N-benzyladriamycin- 14-valerate in the rat. Cancer Chemother Pharmacol 43:419-426.
31. Teraoka K, Hirano M, Yamaguchi K, and Yamashina A (2000) Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2:373-378.
32. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405.
33. Wong AK, Howie J, Petrie JR, and Lang CC (2009) AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 116:607-620.
34. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, and Field LJ (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119:99-106.